XERIS BIOPHARMA HOLDINGS, INC. (XERS) Current Ratio
- Current ratio · latest quarter: Value 1.45×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.45× | Current assets / current liabilities. $274.76M ÷ $189.57M ≈ 1.45× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 274.76M USD | Assets, Current |
| Current obligations | 189.57M USD | Liabilities, Current |
| Cash and equivalents | 121.75M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 58.10M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 80.93M USD | Inventory, Net |
| Payables | 9.34M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 63.78M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $274.76M | $189.57M | $121.75M | (m) | $58.10M | $80.93M | $9.34M | $63.78M | 1.45× |
| 2026-03-31 | $251.68M | $118.59M | $111.75M | (m) | $56.30M | $74.23M | $11.47M | (m) | 2.12× |
| 2025-12-31 | $240.31M | $109.57M | $111.04M | (m) | $51.05M | $68.67M | $3.08M | $0.00 | 2.19× |
| 2025-09-30 | $224.02M | $116.20M | $91.60M | (m) | $53.75M | $67.46M | $6.53M | $0.00 | 1.93× |
| 2025-06-30 | $185.58M | $95.17M | $59.28M | (m) | $53.05M | $67.28M | $9.46M | $0.00 | 1.95× |
| 2025-03-31 | $163.49M | $95.07M | $58.44M | (m) | $46.33M | $52.69M | $6.35M | $11.96M | 1.72× |
| 2024-12-31 | $167.66M | $100.44M | $71.62M | (m) | $40.41M | $48.17M | $2.29M | $15.10M | 1.67× |
| 2024-09-30 | $162.80M | $91.01M | $59.23M | (m) | $41.14M | $45.12M | $7.45M | $15.06M | 1.79× |
| 2024-06-30 | $170.34M | $75.49M | $57.60M | (m) | $42.44M | $42.98M | $5.80M | (m) | 2.26× |
| 2024-03-31 | $173.28M | $73.08M | $62.69M | (m) | $37.41M | $40.88M | $7.09M | (m) | 2.37× |
| 2023-12-31 | $156.26M | $95.19M | $67.45M | (m) | $39.20M | $38.84M | $11.56M | $0.00 | 1.64× |
| 2023-09-30 | $158.05M | $87.04M | $46.14M | (m) | $45.97M | $38.14M | $12.08M | (m) | 1.82× |
| 2023-06-30 | $155.74M | $79.68M | $46.17M | (m) | $30.23M | $36.54M | $11.62M | (m) | 1.95× |
| 2023-03-31 | $165.51M | $81.42M | $50.98M | (m) | $30.86M | $29.04M | $11.98M | (m) | 2.03× |
| 2022-12-31 | $186.82M | $73.62M | $121.97M | (m) | $30.83M | $24.73M | $4.61M | (m) | 2.54× |
| 2022-09-30 | $148.92M | $68.56M | $84.11M | (m) | $27.52M | $20.12M | $3.92M | (m) | 2.17× |
| 2022-06-30 | $161.21M | $64.55M | $95.34M | (m) | $25.76M | $17.89M | $6.63M | (m) | 2.50× |
| 2022-03-31 | $177.55M | $66.49M | $103.77M | (m) | $23.38M | $16.87M | $11.09M | (m) | 2.67× |
| 2021-12-31 | $142.60M | $79.04M | $67.27M | (m) | $17.46M | $18.12M | $8.92M | (m) | 1.80× |
| 2021-09-30 | $124.37M | $37.28M | $59.49M | (m) | (m) | $14.24M | $4.29M | (m) | 3.34× |
| 2020-12-31 | $152.21M | $28.21M | $37.60M | (m) | $6.88M | $8.35M | $3.12M | (m) | 5.40× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |